A5054230253- Retinal Diseases and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Drug Transport and Resistance Mechanisms
- Trace Elements in Health
- HIV/AIDS drug development and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Pain Mechanisms and Treatments
- Biosimilars and Bioanalytical Methods
- Glaucoma and retinal disorders
- Complement system in diseases
- Amino Acid Enzymes and Metabolism
- Hepatitis B Virus Studies
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Anesthesia and Pain Management
- Hepatitis C virus research
- Pharmacological Effects and Toxicity Studies
- Retinal Development and Disorders
- Neonatal Health and Biochemistry
- Peripheral Neuropathies and Disorders
- Biochemical and Molecular Research
- Metabolism and Genetic Disorders
- Neuropeptides and Animal Physiology
- Liver Disease Diagnosis and Treatment
Annexon Biosciences (United States)
2021
BioStrategies (United States)
2017
Boehringer Ingelheim (Germany)
2012-2014
Inserm
2014
Hôpital Beaujon
2014
Université Paris Cité
2014
Boehringer Ingelheim (United States)
2014
Délégation Paris 7
2014
ANX005 is a humanized immunoglobulin G4 recombinant antibody against C1q that inhibits its function as the initiating molecule of classical complement cascade. The safety and tolerability are currently being evaluated in phase I trial healthy volunteers ( www.clinicaltrials.gov Identifier: NCT03010046). Inhibition can be applied therapeutically broad spectrum diseases, including acute antibody-mediated autoimmune disease, such Guillain-Barré syndrome (GBS), chronic diseases central nervous...
Digoxin, an orally administered cardiac glycoside cardiovascular drug, has a narrow therapeutic window. Circulating digoxin levels (maximal concentration of ∼1.5 ng/ml) require careful monitoring, and the potential for drug-drug interactions (DDI) is concern. Increases in plasma exposure caused by inhibition P-glycoprotein (P-gp) have been reported. Digoxin also described as substrate various organic anion-transporting polypeptide (OATP) transporters, posing risk that OATPs may result...
Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible, dose-dependent, clinically benign, unconjugated hyperbilirubinemia. Multidisciplinary preclinical and clinical studies were used to characterize mechanisms underlying this In vitro, faldaprevir inhibited key processes involved in bilirubin clearance: UDP glucuronosyltransferase (UGT) 1A1 (UGT1A1) (IC<sub>50</sub> 0.45 <i>µ</i>M), which conjugates bilirubin, hepatic...
Purpose: C1q and the classical complement cascade are key regulators of synaptic pruning, their aberrant activation has been implicated in neurodegenerative ophthalmic diseases including geographic atrophy glaucoma. The antigen-binding fragment antibody ANX007 specifically recognizes globular head groups to block substrate binding functionally inhibit activation. was assessed nonclinical studies biodistribution target engagement eye following intravitreal (IVT) administration cynomolgus...
Abstract Vocacapsaicin is a novel prodrug of trans‐capsaicin (trans‐8‐methyl‐ N ‐vanillyl‐6‐nonenamide) being developed as nonopioid, long‐lasting, site‐specific treatment for postsurgical pain management. The objective these studies was to examine the safety and tolerability vocacapsaicin in an osteotomy model two animal species evaluate bone healing parameters. Rats undergoing unilateral femoral received single perioperative administration (by instillation) (vehicle, 0.15, 0.3, 0.6 mg/kg)....